Keto diet · Alzheimer's

Keto Diet and Alzheimer’s: What to Measure Before You Believe It

The ketogenic diet gives modest, real memory gains in mild cognitive impairment and early Alzheimer’s: ten pooled trials raised MMSE scores 1.25 points without changing daily function, and eight used a supplement. Whether it works in you shows in fasting insulin, lipids, blood ketones, a memory baseline and fat versus lean mass.

The ketogenic diet has a century of proof in epilepsy and a smaller, honest record in memory loss. Whether it is doing anything in you comes down to numbers most visits never collect.

If you have searched keto diet Alzheimer’s, you have met two camps: people who call it a cure and people who call it a fad. The evidence sits in neither. In the video One Correction, Many Diseases, drawn from The Starved Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, the verdict is stated plainly: established for drug-resistant epilepsy, modest but real for mild cognitive impairment and early Alzheimer’s disease, mixed for Parkinson’s disease, preliminary beyond that. Measura [Cardiometabolic and Autonomic Health Analysis] does not prescribe a diet. It measures the terrain a diet is supposed to change, which is the part of the story that usually goes missing.

Why would a keto diet help an Alzheimer’s brain?

The Alzheimer’s brain has trouble taking up glucose, its usual fuel. On dual-tracer PET scans, brain glucose use ran about 11% lower in people with early Alzheimer’s than in healthy older adults, while ketone uptake did not differ. Picture an engine with two fuel lines: one is clogged, the other still flows. Ketones, which the body makes when insulin is low and carbohydrate is scarce, travel through the open line.

Two more drivers ride along. Chronically high insulin feeds insulin resistance inside the brain; in 683 older Manhattan adults, high insulin levels doubled the risk of Alzheimer’s disease. And beta-hydroxybutyrate, the main ketone, quiets an inflammatory switch called the NLRP3 inflammasome in cell and mouse studies. That last finding is laboratory evidence, not a human trial, and it should be read at that level.

The third driver is not biological at all. The ketogenic diet nearly vanished from epilepsy care once anticonvulsant drugs arrived, not because it failed but because a prescription is easier to write than a diet is to support. The same pressure shapes memory care now. Metabolism gets a pamphlet; the drug gets the appointment.

Does the keto diet help Alzheimer’s? What the memory trials found

Three results carry most of the weight.

• A six-month randomized trial gave 122 adults aged 55 and older with mild cognitive impairment a ketogenic MCT drink or a placebo. Recall, verbal fluency and naming improved, and the gains rose with blood ketone levels. That dose-response pattern is the strongest clue that fuel matters.
• A meta-analysis pooled ten randomized trials in 691 patients. Scores on the MMSE, a standard memory screen, rose 1.25 points on average. Daily function did not change. Eight of the ten trials used a supplement, not a whole diet.
• A whole-diet crossover trial in 26 people with probable Alzheimer’s improved daily function and quality of life, but not cognitive scores.

Modest is the honest word. Nobody in these trials got their old self back. Set against the approved anti-amyloid antibodies, which slowed decline by less than a point on an 18-point scale and carry brain swelling as a known risk, modest and real still deserves attention.

The people the trials left out

Here is the detail most summaries skip. The six-month MCT trial screened out people with uncontrolled diabetes, heart, liver or kidney disease, uncontrolled blood pressure or cholesterol, and B12 deficiency. The whole-diet trial excluded abnormal B12, folate and thyroid results. Put simply, the overfed, insulin-resistant patient with a fatty liver was never in the brain trials.

That cuts both ways. The MCT researchers expected prediabetic older adults to respond somewhat less. Yet a 2026 trial at Washington University in St. Louis, which enrolled exactly that patient, found that liver insulin sensitivity improved two to three times more on a ketogenic diet than on a Mediterranean diet when every group lost the same 10% of body weight. Your result cannot be borrowed from a trial that excluded you. It has to be measured.

What does a standard visit check, and what does it miss?

A routine panel reports fasting glucose and hemoglobin A1c. Both are late signals. In 6,538 British civil servants tracked before a diabetes diagnosis, insulin sensitivity was already sliding years before fasting glucose climbed. A person can carry heavy insulin resistance behind a normal glucose and be told all is well. Dr. Padda’s clinic treats a fasting insulin above 10 µIU/mL as high risk; that is his practice cutoff, not a laboratory range.

A routine visit also seldom records a memory baseline, seldom separates fat from muscle when the scale moves, and seldom follows LDL particles after someone changes how they eat. Those gaps matter, because each one is a number the ketogenic trials actually tracked.

The numbers worth having before and after

If you and your physician decide a supervised trial of ketogenic eating makes sense, these measurements turn it from a hope into a result:

• Fasting insulin and lipids. Laboratory panels show where insulin, glucose and cholesterol sit before any change. Across 62 randomized trials in adults, ketogenic diets lowered triglycerides by about 19.96 mg/dL while raising LDL cholesterol by about 8.49 mg/dL, so the lipid picture deserves a repeat check rather than an assumption.
• Ketone level. In the diet trials with positive results, blood beta-hydroxybutyrate ran between 0.95 and 1.3 mmol/L. Ask your physician how your protocol will check it. A diet called ketogenic but never measured is only a menu.
• Memory and thinking. A cognitive assessment gives you a documented starting point, so a later score has something to be compared against.
• Fat versus lean mass. The whole-diet trial reported weight loss of 2.62 kg. Bioimpedance body composition estimates how much of a change came from fat and how much from muscle, which a bathroom scale cannot tell you.

Measura measures and reports. It does not diagnose Alzheimer’s disease and does not treat it. Results go to your physician, who decides what they mean for you.

Safety, and the family-history question

Ketogenic therapy is a medical intervention. The book’s companion material is explicit that anyone taking medication for diabetes or blood pressure, anyone pregnant or breastfeeding, and anyone with kidney, liver, gallbladder or pancreatic disease or a history of disordered eating needs medical supervision for a significant diet change. Medication questions belong with the prescriber before the first meal changes, never after.

People who carry APOE4, the strongest common genetic risk for late-onset Alzheimer’s, often ask whether any of this applies to them. Among 2,157 Swedish adults, all at least 60 years old, the carriers who ate the most meat, roughly 900 grams a week, did not show the extra dementia risk their genes predicted. That is one observational study, and supplement trials in carriers point in different directions. What the research agrees on is that carriers are unusually sensitive to diet and metabolism. Which way that sensitivity runs in one person is a measurement question. Genes set the odds; terrain has a great deal to say about the outcome.

What to do with this

Unmeasured is unmanaged. The ketogenic record is credible precisely because researchers measured ketones, scores and lipids instead of taking the diet on faith. You deserve the same standard. Ask for a fasting insulin number, a cognitive baseline and a body composition reading before anyone decides what your brain needs, then ask for them again. The trial-by-trial evidence is in the Chapter 9 companion evidence guide, and what an evaluation before symptoms looks like continues in measuring for dementia prevention. The mechanism behind the diet, a fuel the insulin-resistant brain can still take up, is covered in ketones as brain fuel.

Frequently asked questions

References

• Fortier, M., Castellano, C.-A., St-Pierre, V., Myette-Côté, É., Langlois, F., Roy, M., Morin, M.-C., Bocti, C., Fulop, T., Godin, J.-P., Delannoy, C., Cuenoud, B., & Cunnane, S. C. (2021). A ketogenic drink improves cognition in mild cognitive impairment: Results of a 6-month RCT. Alzheimer’s & Dementia, 17(3), 543–552. https://doi.org/10.1002/alz.12206
• Rong, L., Peng, Y., Shen, Q., Chen, K., Fang, B., & Li, W. (2024). Effects of ketogenic diet on cognitive function of patients with Alzheimer’s disease: A systematic review and meta-analysis. The Journal of Nutrition, Health and Aging, 28(8), 100306. https://doi.org/10.1016/j.jnha.2024.100306
• Phillips, M. C. L., Deprez, L. M., Mortimer, G. M. N., Murtagh, D. K. J., McCoy, S., Mylchreest, R., Gilbertson, L. J., Clark, K. M., Simpson, P. V., McManus, E. J., Oh, J.-E., Yadavaraj, S., King, V. M., Pillai, A., Sequeira, B., Rodgers, B., Wiltshire, C., Tanner, S., & Tisch, S. (2021). Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease. Alzheimer’s Research & Therapy, 13(1), 51. https://doi.org/10.1186/s13195-021-00783-x
• Croteau, E., Castellano, C. A., Fortier, M., Bocti, C., Fulop, T., Paquet, N., & Cunnane, S. C. (2018a). A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer’s disease. Experimental Gerontology, 107, 18–26. https://doi.org/10.1016/j.exger.2017.07.004
• Petersen, M. C., Smith, G. I., Farabi, S. S., Palacios, H. H., Shankaran, M., Hellerstein, M. K., Patterson, B. W., & Klein, S. (2026). Effect of diet macronutrient content on the cardiometabolic response to weight loss: A randomized clinical trial. Cell Metabolism. Advance online publication. https://doi.org/10.1016/j.cmet.2026.07.020
• Chang, C., Liu, Y., Rohani, P., Khodadadi, N., Prabahar, K., & Sohouli, M. H. (2026). The impact of the ketogenic diet on the lipid profile in adults: A comprehensive review and meta-regression analysis of randomized controlled trials. Endocrine Practice, 32(5), 819–828. https://doi.org/10.1016/j.eprac.2026.01.009
• Norgren, J., Carballo-Casla, A., Grande, G., Börjesson-Hanson, A., Xu, H., Eriksdotter, M., Laukka, E. J., & Garcia-Ptacek, S. (2026). Meat consumption and cognitive health by APOE genotype. JAMA Network Open, 9(3), Article e266489. https://doi.org/10.1001/jamanetworkopen.2026.6489
• Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2004). Hyperinsulinemia and risk of Alzheimer disease. Neurology, 63(7), 1187-1192. https://doi.org/10.1212/01.wnl.0000140292.04932.87
• Tabák, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimäki, M., & Witte, D. R. (2009). Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: An analysis from the Whitehall II study. The Lancet, 373(9682), 2215-2221. https://doi.org/10.1016/S0140-6736(09)60619-X
• Youm, Y.-H., Nguyen, K. Y., Grant, R. W., Goldberg, E. L., Bodogai, M., Kim, D., D’Agostino, D., Planavsky, N., Lupfer, C., Kanneganti, T. D., Kang, S., Horvath, T. L., Fahmy, T. M., Crawford, P. A., Biragyn, A., Alnemri, E., & Dixit, V. D. (2015). The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nature Medicine, 21(3), 263–269. https://doi.org/10.1038/nm.3804

Related reading

• Gum Disease and Dementia: What Is Proven and What to Measure
• Dementia Prevention Starts With Numbers You Can Measure Now
• Laboratory Panels

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, medical director of Measura. Last reviewed September 12, 2026.